Provided By GlobeNewswire
Last update: Jul 15, 2025
NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies, today announced the publication of a peer-reviewed article titled “CAR-iNKT Cells: Redefining the Frontiers of Cellular Immunotherapy” in Frontiers in Immunology. The publication, authored by leading experts in iNKT biology, underscores the power of iNKT cells as the next-generation off-the-shelf platform for treating solid tumors—where conventional cell therapies have failed to deliver lasting results.
Read more at globenewswire.comNASDAQ:INKT (7/29/2025, 4:30:02 PM)
16.7
-2.01 (-10.74%)
Find more stocks in the Stock Screener